Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBart Rijnders

About this trial

Invasive aspergillosis (IA) is the most common mould infection in immunocompromised patients with haematological disease. Voriconazole, a triazole, improves overall survival of patients with an IA and is the mainstay of therapy. Resistance of A. Fumigatus emerged as an important clinical problem and infections with azole resistant Aspergillus have a high mortality. Nowhere in the world, azole resistance is more prevalent than in the Netherlands. Rapid detection of resistance is key to improve the patient's outcome but fungal cultures take time and are often negative. The investigators aim to detect azole resistance associated mutations in fungal DNA extracted directly from serum or plasma to accelerate diagnosis and improve outcome of patients infected with azole resistant A. fumigatus.

Eligibility criteria

Qualifiers

18 years or older.

Lung CT shows lesions that fulfil the EORTC/MSG radiological criteria of possible invasive fungal infection.

A bronchoalveolar lavage is planned or has been performed <48hrs earlier

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Aspergillus PCR

Treatment groups

No treatment groups listed

Sponsors and collaborators

Bart Rijnders

Lead sponsor

Erasmus Medical Center

Sponsor institution